These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 9787320)

  • 1. Successful treatment of essential thrombocythemia evolving into agnogenic myeloid metaplasia with interferon-alpha.
    Kikawa Y; Fukumoto Y; Obata K; Tamura S; Takeuchi M; Tanizawa A; Mayumi M
    J Pediatr Hematol Oncol; 1998; 20(5):463-6. PubMed ID: 9787320
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long term treatment of myeloproliferative disease with interferon-alpha-2b: feasibility and efficacy.
    Gilbert HS
    Cancer; 1998 Sep; 83(6):1205-13. PubMed ID: 9740087
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Chronic myeloproliferative diseases].
    Sréter L
    Orv Hetil; 1998 Jul; 139(30):1779-83. PubMed ID: 9718944
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnosis and treatment of thrombocythemia in myeloproliferative disorders.
    Gilbert HS
    Oncology (Williston Park); 2001 Aug; 15(8):989-96, 998; discussion 999-1000,1006,1008. PubMed ID: 11548978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Leukemogenic risk of hydroxyurea therapy in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
    Nand S; Stock W; Godwin J; Fisher SG
    Am J Hematol; 1996 May; 52(1):42-6. PubMed ID: 8638610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leukemia with megakaryocytic differentiation following essential thrombocythemia and myelofibrosis. Case report and review of the literature.
    Patiño-Sarcinelli F; Knecht H; Pechet L; Pihan G; Savas L; Snyder LM
    Acta Haematol; 1996; 95(2):122-8. PubMed ID: 8638441
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interferon in the treatment of myeloproliferative diseases.
    Silver RT
    Semin Hematol; 1990 Jul; 27(3 Suppl 4):6-14. PubMed ID: 2115694
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenectomy in chronic myeloid leukemia and myelofibrosis with myeloid metaplasia.
    Mesa RA; Elliott MA; Tefferi A
    Blood Rev; 2000 Sep; 14(3):121-9. PubMed ID: 10986148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Left ventricular mural thrombus in a patient with thrombocytosis and agnogenic myeloid metaplasia.
    Baker KM; Hess CE; Ayers CR; Johns DW; Mentzer RM; Wellsons HA; Taylor GJ; Martin RP
    Arch Intern Med; 1981 Oct; 141(11):1527-9. PubMed ID: 7283566
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Essential thrombocytosis: diagnostic and treatment dilemmas.
    Dugan V; Higginbotham R; Gilbert J; Lipscomb G; Lopez FA
    J La State Med Soc; 2003; 155(6):306-13. PubMed ID: 14750750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Primary (essential) thrombocythemia versus initial (hyperplastic) stages of agnogenic myeloid metaplasia with thrombocytosis--a critical evaluation of clinical and histomorphological data.
    Thiele J; Zankovich R; Steinberg T; Kremer B; Fischer R; Diehl V
    Acta Haematol; 1989; 81(4):192-202. PubMed ID: 2474228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Successful treatment of primary myelofibrosis with thrombocytosis during pregnancy with alfa-interferon].
    Gotić M; Cvetković M; Bozanović T; Cemerikić V
    Srp Arh Celok Lek; 2001; 129(11-12):304-8. PubMed ID: 11928616
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 1-(2-Chloroethyl)-cyclohexyl-nitrosourea-induced remission in essential thrombocythemia.
    Leoni F; Grossi A; Rossi Ferrini P
    Acta Haematol; 1983; 69(3):180-3. PubMed ID: 6404101
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Secondary myelofibrosis with metastatic breast cancer simulating agnogenic myeloid metaplasia: report of a case and review of the literature.
    Yablonski-Peretz T; Sulkes A; Polliack A; Weshler Z; Okon E; Catane R
    Med Pediatr Oncol; 1985; 13(2):92-6. PubMed ID: 3982370
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Myeloid metaplasia of the central nervous system in patients with myelofibrosis and agnogenic myeloid metaplasia. Report of 3 cases and review of the literature.
    Ligumski M; Polliack A; Benbassat J
    Am J Med Sci; 1978; 275(1):99-103. PubMed ID: 665716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegylated interferon for the treatment of early myelofibrosis: correlation of serial laboratory studies with response to therapy.
    O'Neill C; Siddiqi I; Brynes RK; Vergara-Lluri M; Moschiano E; O'Connell C
    Ann Hematol; 2016 Apr; 95(5):733-8. PubMed ID: 26961933
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma matrix metalloproteinase and tissue inhibitor of metalloproteinase in patients with agnogenic myeloid metaplasia or idiopathic primary myelofibrosis.
    Wang JC; Novetsky A; Chen C; Novetsky AD
    Br J Haematol; 2002 Dec; 119(3):709-12. PubMed ID: 12437648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Familial myeloproliferative syndrome.
    Pérez-Encinas M; Bello JL; Pérez-Crespo S; De Miguel R; Tome S
    Am J Hematol; 1994 Jul; 46(3):225-9. PubMed ID: 8192153
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegylated interferon α2a induces complete remission of acute myeloid leukemia in a postessential thrombocythemia myelofibrosis permitting allogenic stem cell transplantation.
    Dagorne A; Douet-Guilbert N; Quintin-Roue I; Guillerm G; Couturier MA; Berthou C; Ianotto JC
    Ann Hematol; 2013 Mar; 92(3):407-9. PubMed ID: 22941306
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.